Returns | 1W : -2% , 1M : -5.5%,1Y : 3.4% |
LT :   |
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : High |
ST :   |
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Peers & Returns | 1W | 1M | 1Y |
HESTER BIOSCIENCES LTD | -2% | -5.5% | 3.4% |
SUN PHARMACEUTICAL INDUSTRIES LTD | -1.1% | 0.1% | 30.6% |
DR REDDYS LABORATORIES LTD | -0.4% | -3.6% | 65.1% |
DIVIS LABORATORIES LTD | -0.6% | -3.9% | 94.4% |
CIPLA LTD | 0.8% | -2% | 72.3% |
BIOCON LTD | -12.3% | -18.6% | 51% |
AUROBINDO PHARMA LTD | 0.8% | 3.8% | 81.4% |
LUPIN LTD | 1.6% | 12.1% | 44.7% |
TORRENT PHARMACEUTICALS LTD | 2.1% | -3.9% | 37% |
Ratio | Value |
---|---|
P/E P/B P/S |
45.15
P/E Calculated based on EPS of 36.7
[ Mar2020 - Standalone Results ] 6.94
P/B Calculated based on Book Value of 238.73
[ Mar2020 - Standalone Results ] 8.53
P/S Calculated based on Revenues of 165.07 Cr
[ TTM - Standalone Results ] |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
86% 63% 72% |
Pledged Shares |
0 % |
---|---|
As on : Sep2020 | |
If less than 25% | Good |
If between 25% and 50% | Neutral |
If greater than 50% | Bad |